Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.
Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L.
Foldi J, et al. Among authors: horowitz n.
NPJ Breast Cancer. 2022 Feb 3;8(1):17. doi: 10.1038/s41523-022-00392-3.
NPJ Breast Cancer. 2022.
PMID: 35115541
Free PMC article.
No abstract available.